FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2994753669> ?p ?o ?g. }

• W2994753669 endingPage "315021" @default.
• W2994753669 startingPage "bjophthalmol" @default.
• W2994753669 abstract "Background/aims To understand changes in disease activity as assessed by leakage and retinal fluid status in patients with neovascular age-related macular degeneration (nAMD) receiving fixed dosing with an anti-vascular endothelial growth factor (anti-VEGF) agent. Methods In the phase III VIEW 1 ( NCT00509795 ) and VIEW 2 ( NCT00637377 ) studies, eyes with nAMD were treated with intravitreal aflibercept or ranibizumab. Independent, masked reading centres determined the presence/absence of leakage (fluorescein angiography) and retinal fluid (optical coherence tomography) at baseline, week 24 and week 52. In this integrated, post hoc analysis of the VIEW studies, the relationship between leakage/fluid status and best-corrected visual acuity (BCVA) was assessed. The impact of baseline lesion type (predominantly classic (PC), minimally classic (MC), occult) was also evaluated. Data from all treatment groups were pooled. Results 2373 eyes were included in this analysis. At baseline, 95.4% of eyes presented with both leakage and fluid. By week 52, leakage and fluid were present in 16.0% of eyes. Mean BCVA gains at week 52 were numerically greater in eyes without leakage and fluid versus eyes with both leakage and fluid (10.3 vs 9.2 letters). At week 52, 11.6%, 15.3% and 20.1% of eyes with PC, MC and occult lesions, respectively, had both leakage and fluid present. Conclusion In this post hoc analysis, fixed dosing with an anti-VEGF agent over 52 weeks eliminated disease activity (absence of both leakage and fluid) in most eyes. The effect of anti-VEGF treatment on leakage/fluid status favoured PC versus occult lesions." @default.
• W2994753669 created "2019-12-26" @default.
• W2994753669 creator A5063601469 @default.
• W2994753669 creator A5063622809 @default.
• W2994753669 creator A5073337092 @default.
• W2994753669 date "2019-12-11" @default.
• W2994753669 modified "2023-10-17" @default.
• W2994753669 title "Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies" @default.
• W2994753669 cites W1789824814 @default.
• W2994753669 cites W1968189763 @default.
• W2994753669 cites W1999477909 @default.
• W2994753669 cites W2004117352 @default.
• W2994753669 cites W2042321005 @default.
• W2994753669 cites W2060747351 @default.
• W2994753669 cites W2085712747 @default.
• W2994753669 cites W2124415048 @default.
• W2994753669 cites W2233259956 @default.
• W2994753669 cites W2469262027 @default.
• W2994753669 cites W2563886653 @default.
• W2994753669 cites W2754696091 @default.
• W2994753669 cites W2767258002 @default.
• W2994753669 doi "https://doi.org/10.1136/bjophthalmol-2019-315021" @default.
• W2994753669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31826853" @default.
• W2994753669 hasPublicationYear "2019" @default.
• W2994753669 type Work @default.
• W2994753669 sameAs 2994753669 @default.
• W2994753669 citedByCount "4" @default.
• W2994753669 countsByYear W29947536692021 @default.
• W2994753669 countsByYear W29947536692022 @default.
• W2994753669 crossrefType "journal-article" @default.
• W2994753669 hasAuthorship W2994753669A5063601469 @default.
• W2994753669 hasAuthorship W2994753669A5063622809 @default.
• W2994753669 hasAuthorship W2994753669A5073337092 @default.
• W2994753669 hasConcept C118487528 @default.
• W2994753669 hasConcept C141071460 @default.
• W2994753669 hasConcept C2776403814 @default.
• W2994753669 hasConcept C2776694085 @default.
• W2994753669 hasConcept C2777802072 @default.
• W2994753669 hasConcept C2778257484 @default.
• W2994753669 hasConcept C2778749236 @default.
• W2994753669 hasConcept C2780248432 @default.
• W2994753669 hasConcept C2780827179 @default.
• W2994753669 hasConcept C2781100027 @default.
• W2994753669 hasConcept C2781156865 @default.
• W2994753669 hasConcept C71924100 @default.
• W2994753669 hasConceptScore W2994753669C118487528 @default.
• W2994753669 hasConceptScore W2994753669C141071460 @default.
• W2994753669 hasConceptScore W2994753669C2776403814 @default.
• W2994753669 hasConceptScore W2994753669C2776694085 @default.
• W2994753669 hasConceptScore W2994753669C2777802072 @default.
• W2994753669 hasConceptScore W2994753669C2778257484 @default.
• W2994753669 hasConceptScore W2994753669C2778749236 @default.
• W2994753669 hasConceptScore W2994753669C2780248432 @default.
• W2994753669 hasConceptScore W2994753669C2780827179 @default.
• W2994753669 hasConceptScore W2994753669C2781100027 @default.
• W2994753669 hasConceptScore W2994753669C2781156865 @default.
• W2994753669 hasConceptScore W2994753669C71924100 @default.
• W2994753669 hasFunder F4320311600 @default.
• W2994753669 hasLocation W29947536691 @default.
• W2994753669 hasOpenAccess W2994753669 @default.
• W2994753669 hasPrimaryLocation W29947536691 @default.
• W2994753669 hasRelatedWork W16396968 @default.
• W2994753669 hasRelatedWork W1964041030 @default.
• W2994753669 hasRelatedWork W2039590936 @default.
• W2994753669 hasRelatedWork W2170979873 @default.
• W2994753669 hasRelatedWork W2418354957 @default.
• W2994753669 hasRelatedWork W2551646801 @default.
• W2994753669 hasRelatedWork W2623420165 @default.
• W2994753669 hasRelatedWork W2805081295 @default.
• W2994753669 hasRelatedWork W3215100674 @default.
• W2994753669 hasRelatedWork W4236181141 @default.
• W2994753669 isParatext "false" @default.
• W2994753669 isRetracted "false" @default.
• W2994753669 magId "2994753669" @default.
• W2994753669 workType "article" @default.